16th Dec 2015 14:06
LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that it had received positive top-line results from its phase III study into sirukumab for the treatment of patients with moderately to severely active rheumatoid arthritis.
The treatment is in development as part of a collaboration with Janssen Biologics BV.
Full results from three phase III studies of the drug will be presented at forthcoming scientific conferences and submitted for publication in peer-reviewed journals, Glaxo said. It expects regulatory applications for sirukumab to be made in 2016.
Shares in GlaxoSmithKline were up 1.7% at 1,330.97 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline